ENTA
ENANTA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$10.71
−3.95%Oct 28, 2026, 12:16 UTC
ENANTA PHARMACEUTICALS INC appointed Tara L. Kieffer as chief operating officer, effective October 28, 2026.
Oct 26, 2026, 11:00 UTC
Enanta Pharmaceuticals announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 trial of zelicapavir in adults at high risk of severe outcomes from RSV infection.
Source:Oct 15, 2026, 12:30 UTC
ENANTA PHARMACEUTICALS INC reported that group net gaming revenue grew 4% year over year in the third quarter of 2026.
Source:Oct 13, 2026, 11:00 UTC
ENANTA PHARMACEUTICALS INC announced that data for zelicapavir will be presented at IDWeek 2026, scheduled for October 21–24, 2026.
Source:Sep 16, 2026, 08:45 UTC
Entain launched a consultation to cut around 400 customer care jobs, about a fifth of its 2,000-strong global customer care workforce across 11 countries including the UK, citing increased UK gambling taxes.
Source:Aug 10, 2026, 22:11 UTC
Enanta Pharmaceuticals reported a Q3 2026 loss of $0.67 per share, missing the Zacks Consensus Estimate of a loss of $0.37, and compared to a loss of $0.85 per share a year ago.
Source:Jun 23, 2026, 09:10 UTC
AbbVie received European Commission approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus in the European Union.
Source: